<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Use of recombinant human thrombopoietin (rHuTPO) after intensive chemotherapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Use of recombinant human thrombopoietin (rHuTPO) after intensive chemotherapy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Use of recombinant human thrombopoietin (rHuTPO) after intensive chemotherapy</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Patients with gynecologic malignancy were treated with high-dose carboplatin on day 1 of cycle 1 (gray columns, chemotherapy alone) and cycle 2 (blue columns, chemotherapy plus rHuTPO, administered daily). The administration of rHuTPO significantly increased the nadir platelet count, decreased the duration of thrombocytopenia, and reduced the need for platelet transfusion.</div><div class="graphic_footnotes">rHuTPO: recombinant human thrombopoietin.<br/>* p&lt;0.05.</div><div class="graphic_reference">Data from Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000; 132:364.</div><div id="graphicVersion">Graphic 77335 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
